Literature DB >> 8761322

Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemia-induced epilepsy.

H L Edmonds1, Y D Jiang, P Y Zhang, R P Shank.   

Abstract

Topiramate, a structurally novel anticonvulsant, and phenytoin were evaluated in a rat model of ischemia-induced epilepsy. In this model a transient global cerebral ischemia is induced by cardiac compression. By precisely controlling the experimental conditions the procedure causes reproducible neurological deficits that include audiogenic epileptic seizures. The seizures can be broadly separated into three types reflecting the degree of severity: wild running, clonic seizures, and tonic extension seizures of the forelimbs and hindlimbs. Topiramate and phenytoin blocked all three types of seizures. Calculated ED50 values for topiramate 1 hr after oral administration were 8.2, 13.0 and 36.1 mg/kg for blockade of tonic extension seizures, clonic seizures and wild running, respectively. Corresponding ED50 values for phenytoin were 5.0, 10.8 and 20.7 mg/kg. These results support the concept that the anticonvulsant activity of these drugs is due primarily to an ability to block the spread of seizures.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8761322     DOI: 10.1016/0024-3205(96)00379-7

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

Review 1.  Topiramate. Clinical profile in epilepsy.

Authors:  R C Sachdeo
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

2.  Failure of ischemic neuroprotection by potentiators of gamma-aminobutyric acid.

Authors:  Ken Madden; Wayne Clark; Nicola Lessov
Journal:  Clin Med Res       Date:  2003-04

3.  Ethosuximide and phenytoin dose-dependently attenuate acute nonconvulsive seizures after traumatic brain injury in rats.

Authors:  Andrea Mountney; Deborah A Shear; Brittney Potter; Sean R Marcsisin; Jason Sousa; Victor Melendez; Frank C Tortella; Xi-Chun M Lu
Journal:  J Neurotrauma       Date:  2013-10-18       Impact factor: 5.269

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.